Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine

Nasamon Wanlapakorn, Ritthideach Yorsaeng, Harit Phowatthanasathian, Nungruthai Suntronwong, Sitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
doi: https://doi.org/10.1101/2021.11.20.21266644

Article Information

doi 
https://doi.org/10.1101/2021.11.20.21266644
History 
  • November 21, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Nasamon Wanlapakorn1,
  2. Ritthideach Yorsaeng1,
  3. Harit Phowatthanasathian1,
  4. Nungruthai Suntronwong1,
  5. Sitthichai Kanokudom1,
  6. Natthinee Sudhinaraset1 and
  7. Yong Poovorawan1,2,*
  1. 1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  2. 2FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand
  1. ↵*Address for correspondence: Yong Poovorawan, M.D. Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. E-mail: yong.p{at}chula.ac.th
Back to top
Posted November 21, 2021.
Download PDF
Data/Code
Email
Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
Nasamon Wanlapakorn, Ritthideach Yorsaeng, Harit Phowatthanasathian, Nungruthai Suntronwong, Sitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
medRxiv 2021.11.20.21266644; doi: https://doi.org/10.1101/2021.11.20.21266644
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area